Sanofi to build new manufacturing facility in Toronto

By The Science Advisory Board staff writers

April 1, 2021 -- Sanofi announced an investment of approximately $737 million U.S. in a new vaccine manufacturing facility at its existing site in Toronto, Canada, to provide additional antigen and filling capacity for Sanofi's influenza vaccine.

The investment is intended to strengthen domestic pandemic preparedness and increase global supply of Sanofi's Fluzone high-dose quadrivalent influenza vaccine, which has been recommended for use over standard-dose influenza vaccines in individual adults 65 years and older by the National Advisory Committee on Immunization in Canada.

The Sanofi Pasteur site currently manufactures millions of doses of vaccines annually against pertussis, polio, diphtheria, and tetanus, among others, for more than 60 countries worldwide. Vaccines produced at the new facility on the same site will supply influenza vaccines to Canada, the U.S., and Europe.

Following design, construction, testing, and qualification of the facility and equipment, the new facility will be operational by 2026. The investment will create 300 high quality jobs, according to the company.

GVN adds Sanofi Pasteur as partner against viral threats
The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence...
Sanofi, Translate Bio begin early-stage trials of mRNA COVID-19 vaccine
Sanofi Pasteur, the vaccine unit of Sanofi, is partnering with Translate Bio on a phase I/II clinical trial for MRT5500, a messenger RNA (mRNA) vaccine...
Sirion Biotech, Sanofi to improve AAV capsids
Sirion Biotech has signed a license and collaboration agreement with Sanofi to develop improved tissue-selective adeno-associated virus (AAV) vectors...
Sanofi, GSK start phase II COVID-19 vaccine study
Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.
Sanofi to acquire Kymab for $1.1B
Sanofi has entered into an agreement to acquire monoclonal antibody manufacturer Kymab for an upfront payment of approximately $1.1 billion and up...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter